A common leukemia drug, dasatinib, is showing promise in reducing inflammation associated with psoriasis, according to a new study published in the Journal of Allergy and Clinical Immunology. Researchers at the Centro de Biología Molecular Severo Ochoa (CSIC-UAM) in Spain have identified a previously unknown mechanism driving inflammation in psoriasis and found that dasatinib effectively interrupts this process in laboratory models. This discovery offers a potential new avenue for treating the chronic autoimmune disease, which affects an estimated 2.4% of the population, translating to over 1.1 million diagnosed patients in Spain alone.
Psoriasis manifests as red, scaly patches on the skin, often accompanied by intense itching, burning, and dryness. The condition arises when the immune system becomes overactive, triggering inflammation. While existing treatments can manage symptoms, a deeper understanding of the underlying inflammatory pathways is crucial for developing more targeted and effective therapies. The research team’s work focuses on unraveling the complex signaling within immune cells that fuels this inflammation, specifically the interplay between two key signaling molecules: interleukin-23 (IL-23) and interleukin-17 (IL-17).
Unlocking the Inflammatory Cascade
The study reveals a critical role for a protein called Blk in transmitting the inflammatory signal within cells. IL-23 activates a chain of proteins, ultimately leading to the activation of mTOR complexes – cellular regulators involved in inflammation. Blk acts as a crucial intermediary in this process, connecting the IL-23 signal to the activation of the inflammatory response. “Until now, the role of Blk in the inflammatory cascade of psoriasis was unknown,” explained researchers in their published findings. This discovery positions Blk as a potential new therapeutic target for future psoriasis treatments.
The IL-23/IL-17 pathway is a well-established driver of psoriasis. IL-23 activates immune cells, prompting them to produce IL-17, which contributes to skin inflammation. Current treatments often target these cytokines directly, but understanding *how* the IL-23 signal is transmitted within cells is vital for developing more precise interventions. The research team’s focus on this internal signaling mechanism represents a significant step forward in this area.
Repurposing an Existing Drug
To investigate this process, the researchers employed a strategy known as “drug repurposing” – evaluating existing, approved medications for new therapeutic uses. This approach accelerates the development timeline, as the safety and basic functionality of these drugs are already established. The team screened a collection of approved pharmaceuticals and identified dasatinib, currently used to treat certain types of leukemia, as a promising candidate.
Dasatinib demonstrated a remarkable ability to block the production of IL-17 in immune cells. Experiments showed that the drug effectively shut down the inflammatory signal triggered by IL-23. Further testing in a laboratory model of psoriasis-like skin inflammation confirmed these findings. Treatment with dasatinib reduced key symptoms of the condition, including skin thickening, immune cell accumulation, and the presence of IL-17-producing cells.
Importantly, the drug’s effectiveness was observed both when administered systemically (throughout the body) and when applied directly to the skin. This suggests the potential for developing topical dasatinib formulations – creams or ointments – that could deliver the medication directly to the affected areas, minimizing systemic exposure and potential side effects.
Beyond Psoriasis: Implications for Other Inflammatory Diseases
The findings extend beyond psoriasis, potentially offering insights into other inflammatory conditions driven by the IL-23/IL-17 pathway. The researchers suggest that dasatinib, or similar drugs targeting the newly identified signaling pathway, could be explored as potential treatments for a broader range of inflammatory diseases.
While these results are encouraging, it’s crucial to emphasize that this research is still in its early stages. Further studies are needed to evaluate the safety and efficacy of dasatinib specifically for psoriasis and other inflammatory conditions in human clinical trials. Researchers will need to determine optimal dosages, delivery methods, and potential long-term effects.
The team’s next steps involve conducting more in-depth studies to fully characterize the role of Blk in the inflammatory process and to explore the potential of developing even more targeted therapies. The researchers are likewise planning to investigate the effectiveness of dasatinib in other preclinical models of inflammatory diseases. Updates on their progress will be published in peer-reviewed scientific journals and presented at international conferences.
This article provides information for educational purposes only and is not a substitute for professional medical advice. If you have concerns about psoriasis or any other health condition, please consult with a qualified healthcare provider.
Share your thoughts on this promising research in the comments below, and please share this article with anyone who might find it helpful.
Worth a look
